Pfizer's novel rheumatoid arthritis drug shows Phase II promise
This article was originally published in Scrip
Executive Summary
Pfizer's novel JAK3 inhibitor CP-690550 improved outcomes in patients with rheumatoid arthritis (RA) in two Phase II trials, and the company is now enrolling patients for Phase III trials of the drug.